PATENT CLAIM ANALYSIS

Application Number: 15935294
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "234200"]

Abstract:
A combination of a CDK4/6 inhibitor and an mTOR inhibitor for the treatment of cancer.

Claim (Index 6):
A method of treating cancer comprising administering a first agent that is a cyclin dependent kinase 4 or cyclin dependent kinase 6 (CDK4/6) inhibitor and a second agent that is an mTOR inhibitor wherein the first agent is 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 90.0
- Lexical Diversity: 1.14286
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15003860', '14124753', '14214048', '13786955', '14158358']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7693854558847232
- 35 USC 102 Novelty (BERT): 0.5352654165422603
- Combined Prediction Score: 0.7459734519504768
- Mean Citation Score: 326.48982599999994
- Max Citation Score: 374.88705
- Similarity Product: 331.79078890645803

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test